Benmelstobart Plus Anlotinib Is Unlikely to Be Cost-Effective for Advanced Renal Cell Carcinoma: An Integrated Disease Burden and Cost-Effectiveness Analysis.

Kidney cancer (KC) is an important public-health challenge in China. Although benmelstobart plus anlotinib (BEN + AL) improves survival compared with sunitinib (SUN) for advanced renal cell carcinoma, its economic value in the Chinese healthcare system remains uncertain. Epidemiological trends in KC...

Descripción completa

Detalles Bibliográficos

Publicado en:	Inquiry (00469580) Vol. 63; pp. 1 - 18
Autores principales:	Xu, Haiyan, Wang, Liejiong, Lou, Ying, Qiu, Zhaoqi, Xuan, Feng
Formato:	research tables/charts Journal Article
Publicado:	Sage Publications Inc. 4/9/2026
Acceso en línea:	Ver este registro en EBSCOhost